When to consider patient preference information along the medical product lifecycle?

An overview of decision points and situations

Eline van Overbeeke, Chiara Whichello


22 & 23 October 2018 • IMI Scientific Symposium • Brussels, Belgium

All authors confirmed no conflicts of interest. This presentation and its contents reflects the view of the presenter and not the view of PREFER, IMI, the European Union or EFPIA.
Aims & methods

1. Identify the **decision-making processes and decision points** (industry, regulators, and HTA/payers)
2. Determine which decision points have potential to include **Patient Preference Information (PPI)**
3. Identify **situations** influencing the value of PPI in these decisions

<table>
<thead>
<tr>
<th></th>
<th>Literature review</th>
<th>Interviews (n=143) ¹,²</th>
<th>Validation interviews (n=11)</th>
<th>Focus groups (n=8) ¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

¹ Seven European countries and the US
² Patients, patient representatives, caregivers, industry representatives, regulators, HTA representatives, physicians, and academics
Results: Decision-making processes and decision points

Whichello C, Schölin Bywall K, et al. An overview of critical decision points in the medical product lifecycle: where to include patient preference information in the decision-making process? (Submitted)
Results: Situations influencing the value of PPI

- Patient population
- Product characteristics
- Market
- Familiarity of assessors
- Attitudes of assessors


Conclusions

1. A total of **16 decision points** were identified throughout the MPLC

2. Stakeholders think **PPI is important** in decision-making, but still **no systematic approach** for collecting and using PPI

3. **Situations** and decisions surrounded by **uncertainties** are more **sensitive** to PPI than others